Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.

@article{Fechner2003PharmacokineticsAC,
  title={Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers.},
  author={J{\"o}rg Fechner and Harald Ihmsen and Dirk Hatterscheid and Christine Schiessl and James J. Vornov and Eric Burak and Helmut Schwilden and J{\"u}rgen Sch{\"u}ttler},
  journal={Anesthesiology},
  year={2003},
  volume={99 2},
  pages={303-13}
}
BACKGROUND GPI 15715 (AQUAVAN injection) is a new water-soluble prodrug which is hydrolyzed to release propofol. The objectives of this first study in humans were to investigate the safety, tolerability, pharmacokinetics, and clinical pharmacodynamics of GPI 15715. METHODS Three groups of three healthy male volunteers (aged 19-35 y, 67-102 kg) received 290, 580, and 1,160 mg GPI 15715 as a constant rate infusion over 10 min. The plasma concentrations of GPI 15715 and propofol were measured… CONTINUE READING